MX2016016826A - Tratamiento de la enfermedad renal cronica y otra disfuncion renal utilizando un modulador gdf15. - Google Patents

Tratamiento de la enfermedad renal cronica y otra disfuncion renal utilizando un modulador gdf15.

Info

Publication number
MX2016016826A
MX2016016826A MX2016016826A MX2016016826A MX2016016826A MX 2016016826 A MX2016016826 A MX 2016016826A MX 2016016826 A MX2016016826 A MX 2016016826A MX 2016016826 A MX2016016826 A MX 2016016826A MX 2016016826 A MX2016016826 A MX 2016016826A
Authority
MX
Mexico
Prior art keywords
kidney disease
kidney
chronic kidney
treatment
renal dysfunction
Prior art date
Application number
MX2016016826A
Other languages
English (en)
Spanish (es)
Inventor
Gyuris Jeno
Lerner Lorena
Original Assignee
Aveo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aveo Pharmaceuticals Inc filed Critical Aveo Pharmaceuticals Inc
Publication of MX2016016826A publication Critical patent/MX2016016826A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2016016826A 2014-06-20 2015-06-19 Tratamiento de la enfermedad renal cronica y otra disfuncion renal utilizando un modulador gdf15. MX2016016826A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462015242P 2014-06-20 2014-06-20
PCT/US2015/036794 WO2015196145A1 (en) 2014-06-20 2015-06-19 Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator

Publications (1)

Publication Number Publication Date
MX2016016826A true MX2016016826A (es) 2017-08-28

Family

ID=53724443

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016826A MX2016016826A (es) 2014-06-20 2015-06-19 Tratamiento de la enfermedad renal cronica y otra disfuncion renal utilizando un modulador gdf15.

Country Status (8)

Country Link
US (2) US20170137506A1 (enExample)
EP (1) EP3157953B1 (enExample)
JP (1) JP6768527B2 (enExample)
AU (2) AU2015276800B2 (enExample)
CA (1) CA2952032C (enExample)
EA (1) EA201790051A1 (enExample)
MX (1) MX2016016826A (enExample)
WO (1) WO2015196145A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100689A1 (en) 2012-12-21 2014-06-26 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US10603359B2 (en) 2014-10-30 2020-03-31 Acceleron Pharma Inc. Methods and compositions using GDF15 polypeptides for increasing red blood cells
WO2017109706A1 (en) * 2015-12-22 2017-06-29 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
EP4006049A1 (en) * 2016-01-29 2022-06-01 Washington University Gdf15 in glaucoma and methods of use thereof
JP7138567B2 (ja) 2016-04-27 2022-09-16 ノバルティス アーゲー 成長分化因子１５に対する抗体およびそれらの使用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5733254A (en) 1987-10-15 1998-03-31 Cypress Bioscience, Inc. Method for treating patients suffering from immune thrombocytopenic purpura
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DE69233204T2 (de) 1991-12-13 2004-07-15 Xoma Corp., Berkeley Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
AU2002257420A1 (en) 2001-05-01 2002-11-11 National Research Council Of Canada A system for inducible expression in eukaryotic cells
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
US7919084B2 (en) 2002-06-17 2011-04-05 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
ES2555956T3 (es) * 2004-04-13 2016-01-11 St Vincent's Hospital Sydney Limited Método para modular el apetito
WO2009021293A1 (en) 2007-08-16 2009-02-19 St Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
CN101951921A (zh) 2007-09-17 2011-01-19 比奥尼里斯有限责任公司 用于治疗恶病质的方法和手段
JP2011502106A (ja) * 2007-10-09 2011-01-20 セントビンセンツ ホスピタル シドニー リミテッド マクロファージ阻害性サイトカイン−１を除去又は不活性化して悪液質を治療する方法
WO2010048670A1 (en) * 2008-10-31 2010-05-06 St Vincent's Hospital Sydney Limited Method of prognosis in chronic kidney disease
EP3590537A1 (en) * 2012-09-26 2020-01-08 Julius-Maximilians-Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
WO2014100689A1 (en) * 2012-12-21 2014-06-26 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies

Also Published As

Publication number Publication date
BR112016029820A2 (pt) 2017-10-24
WO2015196145A1 (en) 2015-12-23
JP6768527B2 (ja) 2020-10-14
EA201790051A1 (ru) 2017-04-28
CA2952032A1 (en) 2015-12-23
US11897948B2 (en) 2024-02-13
JP2017519764A (ja) 2017-07-20
US20170137506A1 (en) 2017-05-18
AU2015276800B2 (en) 2021-03-04
AU2015276800A1 (en) 2017-01-05
EP3157953B1 (en) 2021-12-22
CA2952032C (en) 2023-03-14
US20190292252A1 (en) 2019-09-26
AU2021203523A1 (en) 2021-07-01
EP3157953A1 (en) 2017-04-26

Similar Documents

Publication Publication Date Title
MX2016016826A (es) Tratamiento de la enfermedad renal cronica y otra disfuncion renal utilizando un modulador gdf15.
IL255301A0 (en) Optimal mismatch amplification by real-time multiplex-PCR for cell-free DNA estimation
IL263058A (en) Engineered botulinum neurotoxins
DK3659590T3 (da) Sammensætning, partikelformede materialer og fremgangsmåder til fremstilling af partikelformede materialer
PT3274364T (pt) Neurotoxina botulínica manipulada
NZ725568A (en) Modified j-chain
MY197345A (en) Antibody molecules to april and uses thereof
BR112017018715A2 (pt) agonista de receptor de angiotensina ii para tratar fibrose pulmonar
MX2016016617A (es) Tratamiento de mielomas.
GB201811408D0 (en) CD137 Binding Molecules
HK1254672A1 (zh) 治疗痛觉过敏的方法
DK3231771T3 (da) Fremgangsmåde til behandling af vand ved adsorption på aktivt kul og klaring, og dertilsvarende anlæg
EP3433332C0 (en) LIGNIN LIQUID COMPOSITION, LIGNIN-BASED RESIN AND METHOD FOR INCREASING LIGNIN SOLUBILITY
PT3484862T (pt) Compostos, composições e métodos para o tratamento ou a prevenção de um sintoma associado a gota ou hiperuricemia
HK1254673A1 (zh) 阿片受体配体和细胞色素p450抑制剂
EP3130573A4 (en) Lead-free piezoelectric ceramic composition, piezoelectric element using same, production method for lead-free piezoelectric ceramic composition
LT3463432T (lt) Skysta neurotoksino kompozicija, stabilizuota triptofanu arba tirozinu
EP3239332A4 (en) High-strength steel having superior brittle crack arrestability, and production method therefor
SG11202003614WA (en) Method for production of recombinant e. coli asparaginase
EP3130574A4 (en) Lead-free piezoelectric ceramic composition, piezoelectric element using same, production method for lead-free piezoelectric ceramic composition
EP3239330A4 (en) High-strength steel having superior brittle crack arrestability, and production method therefor
BR112019011635A2 (pt) terapia genética para mucopolissacaridose, tipo i
EP3513410A4 (en) REFURBISHMENT, EVALUATION AND REFINING OF PERT SPACE WASTE
DK3634968T3 (da) Heterocykliske forbindelser, der kan anvendes som antibakterielle midler, og fremgangsmåde til fremstilling heraf
EP2982378A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF SEPSIS OR SEPTIC SHOCK WITH ADK PROTEIN AS AN ACTIVE SUBSTANCE